Owkin

Owkin leverages advanced artificial intelligence—including federated learning—to accelerate the identification of new drug candidates, de-risk clinical trials, discover novel biomarkers, and develop diagnostic solutions. Its technology has led to CE-marked diagnostic tools such as MSIntuit CRC for colorectal cancer screening and RlapsRisk BC for early breast cancer prognosis. The company’s pipeline includes both proprietary assets like OKN4395—a selective EP2/4 dual antagonist—and a range of collaborative programs with major pharma partners. Clinical results have demonstrated improved prediction of patient outcomes using deep learning models across several cancers.